.After introducing a phase 3 launch based upon positive midstage end results, iTeos and GSK are even...
.The FDA must be a lot more available as well as joint to unleash a rise in commendations of rare he...
.It's an abnormally hectic Friday for biotech IPOs, along with Zenas BioPharma, MBX and Bicara Thera...
.Atea Pharmaceuticals' antiviral has actually neglected yet another COVID-19 trial, however the biot...
.Neurocrine Biosciences' mental illness program pivot has failed. The biotech was actually unable to...
.Sanofi has actually made a late entrance to the radioligand party, spending one hundred million eur...
.After F2G's 1st attempt to obtain a brand-new training class of antifungal to market was hindered d...
.Moderna has actually vowed to cut R&D investing by $1.1 billion by 2027. The selection to shrink...
.Merely four months after Sanofi bet $80 thousand in beforehand money on Fulcrum Rehabs' losmapimod,...
.Cancer cells business Oncternal Therapeutics is folding all its clinical tests and laying off team,...